Vanda Pharmaceuticals Inc. (VNDA)
VNDA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/0001628280-26-007460-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | VNDA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2006 |
| SEC CIK | 0001347178 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $216.1M |
| Net income | -$220.5M |
| Operating income | -$151.2M |
| Net margin | -102.0% |
| Operating margin | -70.0% |
| Revenue growth | +8.7% |
| Cash | $84.9M |
| Total assets | $488.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.1× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-29 |
| Cash and burn | $61.9M cash; operating cash flow -$34.8M a quarter. | Report 2026-09-30 |
| Shares outstanding | 60,469,687 (2026-10-22); 59,096,630 a year earlier; 57,531,999 three years earlier. | Cover page 2026-10-22 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-02-12 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Washington, District of Columbia, United States | PCAOB Form AP 2026-02-20 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $2.8M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $69.8M | -$22.6M | -$28.4M | $61.9M | No debt tags | $229.3M | 10-Q 2026-10-29 |
| Q2 2026 2026-06-30 | $50.5M | -$62.5M | -$31.1M | $55.9M | No debt tags | $215.7M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $51.7M | -$48.6M | -$50.2M | $54.0M | No debt tags | $217.8M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $57.2M | -$141.2M | -$29.4M | $84.9M | No debt tags | $216.1M | 10-K 2026-02-12 |
| Q3 2025 2025-09-30 | $56.3M | -$22.6M | -$31.6M | $70.0M | No debt tags | $212.1M | 10-Q 2026-10-29 |
| Q2 2025 2025-06-30 | $52.6M | -$27.2M | -$15.3M | $81.0M | No debt tags | $203.5M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $50.0M | -$29.5M | -$33.1M | $111.8M | No debt tags | $201.4M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $53.2M | -$4.9M | -$1.8M | $102.3M | No debt tags | $198.8M | 10-K 2026-02-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-02-12 |
| Latest annual report | 10-K | 2026-02-12 |
| Latest quarterly / interim | 10-Q | 2026-10-29 |
| Latest current report | 8-K | 2026-10-28 |
| Latest proxy | DEFA14A | 2026-04-23 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +4.5% |
| 1 month | -7.2% |
| 3 months | -20.7% |
| Year to date | -54.8% |
| 1 year | -8.1% |
| From 52-week high | -58.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| IMRX | Immuneering Corporation | $3.52 | -5.12% | $228.0M |
| AMRN | Amarin Corporation plc | $11.31 | -0.62% | $233.4M |
| BCYC | Bicycle Therapeutics plc | $3.18 | -5.64% | $222.9M |
| DRUG | Bright Minds Biosciences Inc. | $22.61 | -2.16% | $222.0M |
| ARCT | Arcturus Therapeutics Holdings Inc. | $8.31 | -0.60% | $239.5M |
| FTH | Faeth Therapeutics Inc. | $9.28 | -7.48% | $239.8M |
| BIOA | BioAge Labs Inc. | $5.22 | -5.95% | $239.9M |
| RCKT | Rocket Pharmaceuticals Inc. | $2.16 | -6.09% | $241.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier